Ledipasvir And Sofosbuvir Tablet, Film Coated
NDC Package 72626-2601-1
Package Information
Ledipasvir And Sofosbuvir tablets is if ledipasvir and sofosbuvir tablets are administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. This formulation utilizes a tablet, film coated delivery system. Marketed by Asegua Therapeutics Llc, this product is identified by NDC 72626-2601 and is authorized under FDA application NDA205834.
Identification & Billing
Clinical Specifications
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Hepatitis C Virus NS5A Inhibitor - [EPC] (Established Pharmacologic Class)
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
- RNA Replicase Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 72626 - Asegua Therapeutics Llc
- 72626-2601 - Ledipasvir And Sofosbuvir
- 72626-2601-1 - 2 BLISTER PACK in 1 CARTON / 14 TABLET, FILM COATED in 1 BLISTER PACK
- 72626-2601 - Ledipasvir And Sofosbuvir
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72626-2601-1 identifies a specific commercial package of 2 blister pack in 1 carton / 14 tablet, film coated in 1 blister pack of Ledipasvir And Sofosbuvir, a human prescription drug labeled by Asegua Therapeutics Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 2 billable units per package. This tablet, film coated is formulated for oral use and contains ledipasvir; sofosbuvir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Asegua Therapeutics Llc on January 01, 2019. The current certification is valid through December 31, 2026.
How is this Asegua Therapeutics Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72626260101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.